PMID- 27506680
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20180125
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 103
IP  - 4
DP  - 2017 Feb 15
TI  - High T2-weighted signal intensity is associated with elevated troponin T in 
      hypertrophic cardiomyopathy.
PG  - 293-299
LID - 10.1136/heartjnl-2016-309900 [doi]
AB  - OBJECTIVE: Areas of high signal intensity (HighT2) on T2-weighted cardiovascular 
      magnetic resonance (CMR) imaging have been demonstrated in hypertrophic 
      cardiomyopathy (HCM). It has been hypothesised that HighT2 may indicate active 
      tissue injury in HCM. In this context, we studied HighT2 in relation to cardiac 
      troponin. METHODS: Outpatient HCM patients without a history of coronary artery 
      disease underwent CMR imaging at 1.5 T using T2-weighted, cine and late 
      gadolinium enhancement (LGE) imaging to assess HighT2, left ventricular (LV) 
      function, LV mass and the presence and extent of LGE. Highly sensitive cardiac 
      troponin T (hs-cTnT) was assessed as a marker of injury, with hs-cTnT >/=14 and 
      >3 ng/L defined as an elevated and detectable troponin. RESULTS: HighT2 was 
      present in 28% of patients (28/101). An elevated hs-cTnT was present in 54% of 
      patients with HighT2 (15/28) compared with 14% of patients without HighT2 (10/73) 
      (p<0.001). Hs-cTnT was detectable in 96% of patients with HighT2 (27/28) compared 
      with 66% of patients without HighT2 (48/73) (p=0.002). In case of an undetectable 
      hs-cTnT, HighT2 was only seen in 4% (1/26). In addition, the extent of HighT2 was 
      related with increasing hs-cTnT concentrations (Spearman's rho: 0.42, p<0.001). 
      CONCLUSIONS: In this CMR study of patients with HCM, we observed HighT2 in a 
      quarter of patients, and demonstrated that HighT2 was associated with an elevated 
      hs-cTnT. This observation, combined with the very high negative predictive value 
      of an undetectable hs-cTnT for HighT2, provides supportive evidence for the 
      hypothesis that HighT2 is indicative of recently sustained myocyte injury.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/.
FAU - Gommans, Dh Frank
AU  - Gommans DF
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Cramer, G Etienne
AU  - Cramer GE
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Bakker, Jeannette
AU  - Bakker J
AD  - Department of Radiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
FAU - Michels, Michelle
AU  - Michels M
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
FAU - Dieker, Hendrik-Jan
AU  - Dieker HJ
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Timmermans, Janneke
AU  - Timmermans J
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Fouraux, Michael A
AU  - Fouraux MA
AD  - Department of Clinical Chemistry, Albert Schweitzer Hospital, Dordrecht, The 
      Netherlands.
FAU - Marcelis, Carlo Lm
AU  - Marcelis CL
AD  - Department of Clinical Genetics, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Verheugt, Freek Wa
AU  - Verheugt FW
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Brouwer, Marc A
AU  - Brouwer MA
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Kofflard, Marcel Jm
AU  - Kofflard MJ
AD  - Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20160809
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Biomarkers)
RN  - 0 (Contrast Media)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Troponin T)
RN  - 6HG8UB2MUY (Meglumine)
RN  - L0ND3981AG (gadoterate meglumine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ambulatory Care
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Hypertrophic/*blood/*diagnostic imaging/physiopathology
MH  - Contrast Media/administration & dosage
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Meglumine/administration & dosage
MH  - Middle Aged
MH  - Netherlands
MH  - Organometallic Compounds/administration & dosage
MH  - Pilot Projects
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Troponin T/*blood
MH  - Up-Regulation
MH  - Ventricular Function, Left
EDAT- 2016/08/11 06:00
MHDA- 2017/07/25 06:00
CRDT- 2016/08/11 06:00
PHST- 2016/04/28 00:00 [received]
PHST- 2016/07/21 00:00 [accepted]
PHST- 2016/08/11 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
PHST- 2016/08/11 06:00 [entrez]
AID - heartjnl-2016-309900 [pii]
AID - 10.1136/heartjnl-2016-309900 [doi]
PST - ppublish
SO  - Heart. 2017 Feb 15;103(4):293-299. doi: 10.1136/heartjnl-2016-309900. Epub 2016 
      Aug 9.